Zoetis inc.'s simparica trio receives notice of compliance from health canada's veterinary drugs directorate

Zoetis inc. announces that simparica trio, a once-monthly triple combination antiparasitic medication for dogs, receives notice of compliance from health canada's veterinary drugs directorate. the global canine parasiticides market is more than $4 billion and is the largest therapeutic category in medicines for dogs. the active ingredients of simparica trio are: sarolaner which is active against fleas and ticks; moxidectin effective against heartworm and some intestinal worms; and pyrantel pamoate, effective against certain gastrointestinal nematodes.
ZTS Ratings Summary
ZTS Quant Ranking